Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy Alexandre PoirierMichel L. Tremblay Review 28 November 2022 Pages: 1343 - 1353
First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis Yu FujiwaraHirotaka MiyashitaBobby C. Liaw Review 10 December 2022 Pages: 1355 - 1364
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis Matteo SantoniAlessandro RizzoFrancesco Massari Review 12 January 2023 Pages: 1365 - 1379
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study Alessandro RizzoVeronica MollicaFrancesco Massari Review 25 January 2023 Pages: 1381 - 1394
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure Xiaomi LiXiaoyan DingJinglong Chen Research Open access 28 November 2022 Pages: 1395 - 1403
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study Ann W. SilkSteven J. O’DayJanice M. Mehnert Research Open access 29 November 2022 Pages: 1405 - 1415
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers Piera Filomena FioreAnna Laura Di PacePaola Vacca Research Open access 30 November 2022 Pages: 1417 - 1428
Refurbishment of NK cell effector functions through their receptors by depleting the activity of nTreg cells in Dalton’s Lymphoma-induced tumor microenvironment: an in vitro and in vivo study Munendra Singh TomarRishi Kant SinghArbind Acharya Research 03 December 2022 Pages: 1429 - 1444
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites Alexandra L. MartinChase PowellBradford A. Perez Research 05 December 2022 Pages: 1445 - 1460
Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate Adam L. BurrackEllen J. SpartzIngunn M. Stromnes Research Open access 06 December 2022 Pages: 1461 - 1478
CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer Lei WuShengnan SunGuohai Su Research 06 December 2022 Pages: 1479 - 1492
Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanoma Ami NishikawaYutaro SuzukiAkira Ito Research 07 December 2022 Pages: 1493 - 1504
Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma Zhonglong LiuXiaoyan MengYue He Research Open access 08 December 2022 Pages: 1505 - 1521
Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment Zhi-chen GuoSi-li JingZhong-cheng Gong Research 14 December 2022 Pages: 1523 - 1539
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients Bangwei FangYu WeiYao Zhu Research 16 December 2022 Pages: 1541 - 1551
The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer Saskia J. SantegoetsMarij J. P. WeltersSjoerd H. van der Burg Research Open access 16 December 2022 Pages: 1553 - 1565
CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma Jeong Ryeol KimDonghyuk LeeJoo Young Kim Research 19 December 2022 Pages: 1567 - 1580
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses Rebecca HarrisMahinbanu MammadliMobin Karimi Research Open access 23 December 2022 Pages: 1581 - 1601
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study Jana FriedhoffFelix SchneiderStefan Duensing Research Open access 23 December 2022 Pages: 1603 - 1618
Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment Xiaoyuan WangXiaodong LingJianqun Ma Research 30 December 2022 Pages: 1619 - 1631
Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma Mariam OladejoHong-My NguyenLaurence M. Wood Research 31 December 2022 Pages: 1633 - 1646
NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma Lei ChenShu-Cheng WanZhi-Jun Sun Research 31 December 2022 Pages: 1647 - 1660
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib Lukas HäselbarthAxel KarowMarkus Metzler Research Open access 05 January 2023 Pages: 1661 - 1672
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes Yezhou LiLeilei TianJiayu Zhang Research 09 January 2023 Pages: 1673 - 1683
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy Chunhua WangQuan ChenLiqun Luo Research 09 January 2023 Pages: 1685 - 1698
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer Kenji MorimotoTadaaki YamadaKoichi Takayama Research 09 January 2023 Pages: 1699 - 1707
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study Javier García-CorbachoAlberto IndacocheaFrancesco Schettini Research Open access 10 January 2023 Pages: 1709 - 1723
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study Javier García-CorbachoAlberto IndacocheaFrancesco Schettini Correction Open access 21 February 2023 Pages: 1725 - 1726
Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis Alex WongMaria RileyKevin Ho Research 14 January 2023 Pages: 1727 - 1735
Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis Alex WongMaria RileyKevin Ho Correction 18 February 2023 Pages: 1737 - 1737
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma Tong LuJiayu ZhangLijun Yang Research Open access 16 January 2023 Pages: 1739 - 1750
Correction to: Endosialin‑positive tumor‑derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma Tong LuJiayu ZhangLijun Yang Correction Open access 21 April 2023 Pages: 1751 - 1751
Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with perihilar cholangiocarcinoma at high risk of recurrence Qin-qin LiuXiang-de ShiChao Liu Research 17 January 2023 Pages: 1753 - 1761
Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP+ fibroblasts in stomach adenocarcinoma Xin WangSun HuiWeiqi Sheng Research 17 January 2023 Pages: 1763 - 1778
Prognostic role of the innate immune signature CD163 and “eat me” signal calreticulin in clear cell renal cell carcinoma Tadatsugu AnnoNobuyuki TanakaMototsugu Oya Research 17 January 2023 Pages: 1779 - 1788
Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages Femke A. I. EhlersNiken M. MahaweniLotte Wieten Original Article Open access 19 January 2023 Pages: 1789 - 1801
Human γδ T cells induce CD8+ T cell antitumor responses via antigen-presenting effect through HSP90-MyD88-mediated activation of JNK Shengdong WangHengyuan LiZhaoming Ye Research Open access 21 January 2023 Pages: 1803 - 1821
Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma Sho WakasuTetsuzo TagawaMasaki Mori Original Article 23 January 2023 Pages: 1823 - 1834
LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma Fen ZhaoHui TianLei Fu Research Open access 23 January 2023 Pages: 1835 - 1851
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab Anna SiemiątkowskaMaciej BrylFranciszek K. Główka Research Open access 23 January 2023 Pages: 1853 - 1863
Radiotherapy enhances CXCR3highCD8+ T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells Chih-Liang WangAi-Sheng HoChun-Chia Cheng Research Open access 23 January 2023 Pages: 1865 - 1880
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% E. Pons-TostivintP. HuloJ. Bennouna Research Open access 24 January 2023 Pages: 1881 - 1890
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% E. Pons-TostivintP. HuloJ. Bennouna Correction Open access 27 February 2023 Pages: 1891 - 1892
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors Joshua S. FriedmanTomi JunAdília Hormigo Research 28 January 2023 Pages: 1893 - 1901
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial Masaki ShiotaHideaki MiyakeSNiP-RCC investigators Research 02 February 2023 Pages: 1903 - 1915
Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer Chao WangLinxuan XueDaya Luo Research 02 February 2023 Pages: 1917 - 1932
PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients Mohammad A. Al-MterinKhaled MurshedEyad Elkord Brief Report Open access 27 November 2022 Pages: 1933 - 1939
Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo Stella A. MartomoJeegar Patel Brief Report Open access 01 December 2022 Pages: 1941 - 1950
Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study Cho-Han ChiangYuan-Jen ChenCho-Hung Chiang Brief Report 18 January 2023 Pages: 1951 - 1956
